Bank of New York Mellon’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$156M Buy
2,309,648
+166,507
+8% +$11.1M 0.03% 490
2026
Q1
$135M Sell
2,143,141
-53,701
-2% -$3.74M 0.02% 517
2025
Q4
$146M Sell
2,196,842
-764,536
-26% -$49.4M 0.03% 479
2025
Q3
$199M Sell
2,961,378
-902,950
-23% -$71.5M 0.04% 374
2025
Q2
$337M Sell
3,864,328
-612,325
-14% -$48M 0.06% 265
2025
Q1
$306M Buy
4,476,653
+284,593
+7% +$23.2M 0.06% 274
2024
Q4
$326M Sell
4,192,060
-557,987
-12% -$41.3M 0.06% 275
2024
Q3
$318M Buy
4,750,047
+338,347
+8% +$27.8M 0.06% 275
2024
Q2
$500M Buy
4,411,700
+263,474
+6% +$33.3M 0.09% 199
2024
Q1
$575M Sell
4,148,226
-202,476
-5% -$25.5M 0.11% 176
2023
Q4
$540M Buy
4,350,702
+78,422
+2% +$8.01M 0.11% 167
2023
Q3
$399M Sell
4,272,280
-200,111
-4% -$22.6M 0.09% 197
2023
Q2
$575M Sell
4,472,391
-527,735
-11% -$63.8M 0.12% 157
2023
Q1
$581M Sell
5,000,126
-315,747
-6% -$35.3M 0.13% 155
2022
Q4
$602M Sell
5,315,873
-210,770
-4% -$23.1M 0.14% 150
2022
Q3
$445M Buy
5,526,643
+236,233
+4% +$20M 0.11% 183
2022
Q2
$394M Buy
5,290,410
+285,982
+6% +$26.1M 0.09% 204
2022
Q1
$640M Buy
5,004,428
+272,276
+6% +$29.8M 0.12% 154
2021
Q4
$635M Sell
4,732,152
-135,864
-3% -$19.5M 0.11% 156
2021
Q3
$666M Sell
4,868,016
-56,536
-1% -$7.13M 0.13% 145
2021
Q2
$526M Sell
4,924,552
-164,032
-3% -$15.8M 0.1% 177
2021
Q1
$457M Buy
5,088,584
+134,956
+3% +$12.7M 0.09% 194
2020
Q4
$458M Buy
4,953,628
+151,448
+3% +$13.5M 0.1% 176
2020
Q3
$495M Sell
4,802,180
-435,320
-8% -$45.5M 0.12% 152
2020
Q2
$531M Buy
5,237,500
+1,042,832
+25% +$93.3M 0.14% 134
2020
Q1
$282M Sell
4,194,668
-159,000
-4% -$9.89M 0.09% 188
2019
Q4
$238M Sell
4,353,668
-190,856
-4% -$9.05M 0.06% 286
2019
Q3
$170M Sell
4,544,524
-15,940
-0.3% -$619K 0.05% 352
2019
Q2
$171M Buy
4,560,464
+944,756
+26% +$29.7M 0.05% 368
2019
Q1
$108M Sell
3,615,708
-447,948
-11% -$15.7M 0.03% 548
2018
Q4
$122M Buy
4,063,656
+468,780
+13% +$14.9M 0.04% 439
2018
Q3
$129M Buy
3,594,876
+520,192
+17% +$16.1M 0.03% 508
2018
Q2
$73M Sell
3,074,684
-271,436
-8% -$5.75M 0.02% 765
2018
Q1
$62M Sell
3,346,120
-405,200
-11% -$5.99M 0.02% 861
2017
Q4
$53.8M Sell
3,751,320
-191,836
-5% -$2.49M 0.01% 970
2017
Q3
$48.2M Sell
3,943,156
-9,028,556
-70% -$160M 0.01% 1012
2017
Q2
$237M Buy
12,971,712
+2,784,796
+27% +$51.4M 0.07% 304
2017
Q1
$216M Buy
10,186,916
+7,667,036
+304% +$150M 0.06% 339
2016
Q4
$37.6M Buy
2,519,880
+431,408
+21% +$7.64M 0.01% 1124
2016
Q3
$45.8M Buy
2,088,472
+398,872
+24% +$8.88M 0.01% 940
2016
Q2
$33.5M Sell
1,689,600
-23,172
-1% -$395K 0.01% 1088
2016
Q1
$29.1M Buy
1,712,772
+14,832
+0.9% +$248K 0.01% 1179
2015
Q4
$34.8M Sell
1,697,940
-20,144
-1% -$419K 0.01% 1035
2015
Q3
$36.9M Buy
1,718,084
+21,716
+1% +$485K 0.01% 1033
2015
Q2
$33.9M Sell
1,696,368
-444,476
-21% -$7.81M 0.01% 1131
2015
Q1
$33.4M Sell
2,140,844
-98,212
-4% -$1.48M 0.01% 1132
2014
Q4
$30.8M Buy
2,239,056
+110,760
+5% +$1.36M 0.01% 1170
2014
Q3
$21.3M Buy
2,128,296
+45,872
+2% +$469K 0.01% 1385
2014
Q2
$20.6M Buy
2,082,424
+60,352
+3% +$535K 0.01% 1454
2014
Q1
$20.9M Sell
2,022,072
-144,328
-7% -$1.49M 0.01% 1426
2013
Q4
$19.2M Sell
2,166,400
-26,476
-1% -$210K 0.01% 1473
2013
Q3
$15.5M Buy
2,192,876
+49,324
+2% +$313K ﹤0.01% 1567
2013
Q2
$12M Buy
+2,143,552
New +$10.3M ﹤0.01% 1669

Other funds holding DXCM

Bank of New York Mellon's DXCM Position: Q2 2026 in Review

Bank of New York Mellon increased its DexCom (DXCM) stake by 7.8% in Q2 2026, buying an estimated $11.1M and bringing the position to 2,309,648 shares worth $156M. The position accounts for 0.03% of the portfolio, ranked #490.

Bank of New York Mellon first reported a position in DXCM in Q2 2013 and has held it in 53 quarters since. The position peaked at $666M in Q3 2021. 540 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Bank of New York Mellon held 2,309,648 shares of DexCom worth $156M as of Q2 2026.
  • Bank of New York Mellon bought 166,507 DexCom shares in Q2 2026, an estimated $11.1M.
  • DexCom made up 0.03% of Bank of New York Mellon's portfolio in Q2 2026, its #490 holding.
  • Bank of New York Mellon first reported a position in DexCom in Q2 2013 and has held it in 53 quarters since.
  • Bank of New York Mellon's DexCom position peaked at $666M in Q3 2021.
  • 540 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.